TMCnet News
Money Money Money!!! Sign Up For Our Newsletter!!! (OTCBB: FORC) Force Energy Corp. (NASDAQ: SNPS) Synopsys, Inc. (NASDAQ: SNTA) Synta Pharmaceuticals, Inc. (NASDAQ: SNTS) Santarus, Inc. (NASDAQ: SNWL) SonicWALL, Inc. (NASDAQ: SRCL) Stericycle, Inc.(M2 PressWIRE Via Acquire Media NewsEdge) STOCK MARKETING INC PRESENTS : (OTCBB: FORC) Force Energy Corp. (NASDAQ: SNPS) Synopsys, Inc. (NASDAQ: SNTA) Synta Pharmaceuticals, Inc. (NASDAQ: SNTS) Santarus, Inc. (NASDAQ: SNWL) SonicWALL, Inc. (NASDAQ: SRCL) Stericycle, Inc. www.StockMarketingInc.com To sign up for our free Profiles & Alerts :: visit http://www.StockMarketingInc.com Email us!! [email protected] OR CALL 1-866-583-8960 ------------------------------------------------------------------------------------------------------------------------------------------------------------ (OTCBB: FORC) Force Energy Corp. BREAKING NEWS!! Force Energy Corp. Provides Shareholder Update DENVER, COLORADO, Oct 13, 2009 -- Force Energy Corp. (OTCBB:FORC)(FRANKFURT: FC2) (hereafter "Force", "the Company"), is pleased to provide the following update on the Company. Force Energy has raised $1 million in equity financing to date for the acquisition of low cost/high yield prospects. This financing has enabled the company to acquire significant working interest in both the Diamond Springs Prospect located within the Wind River Basin of Wyoming as well as the Hayter Prospect, located in Hayter, Alberta. Force Energy has engaged Continental Production Co. to be the operator on drilling activities for the Diamond Springs Prospect. The Company intends to permit up to three wells on the prospect within the next sixty days to enable not only the start of our drill program this drilling season, but also to maximize the potential for drill rig productivity and expansion. About Force Energy Corp. Force Energy Corp. is an Oil & Gas Exploration and Development Company based in Denver, CO with a focus on Wyoming. Using a geology-based methodology, the US Geological Survey estimate a mean of 2.4 trillion cubic feet of undiscovered natural gas and a mean of 41 million barrels of undiscovered oil in the Wind River Basin Province of Wyoming. Force Energy Corp. has acquired 75% working interest in the Diamond Springs Prospect located within this prolific area. The Company's shares are publicly traded on the OTCBB under the ticker symbol FORC. On behalf of the Board of Directors FORCE ENERGY CORP. Legal Notice Regarding Forward-Looking Statements Legal Notice Regarding Forward-Looking Statements in this news release that are not historical facts are forward-looking statements that are subject to risks and uncertainties. Forward- looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined, and assumptions of management. Forward looking statements are generally, but not always, identified by the words "expects", "plans", "anticipates", "has", "believes", "intends", "estimates", "projects", "aims", "potential", "goal", "objective", "prospective", and similar expressions or that events or conditions "will", "would", "may", "can", "could" or "should" occur. Information concerning oil or natural gas reserve estimates may also be deemed to be forward looking statements, as it constitutes a prediction of what might be found to be present when and if a project is actually developed. Actual results may differ materially from those currently anticipated due to a number of factors beyond the reasonable control of the Company. It is important to note that actual outcomes and the Company's actual results could differ materially from those in such forward-looking statements. Factors that could cause actual results to differ materially include misinterpretation of data, inaccurate estimates of oil and natural gas reserves, the uncertainty of the requirements demanded by environmental agencies, the Company's ability to raise financing for operations, breach by parties with whom we have contracted, inability to maintain qualified employees or consultants because of compensation or other issues, competition for equipment, inability to obtain drilling permits, potential delays or obstacles in drilling operations and interpreting data, the likelihood that no commercial quantities of oil or gas are found or recoverable, and our ability to participate in the exploration of, and successful completion of development programs on all aforementioned prospects and leases. Additional information on risks for the Company can be found in the Company's periodic filings filed from time to time with US Securities and Exchange Commission at www.sec.gov. This press release does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "Securities Act"). They may not be offered or sold in the United States (as defined in Regulation S under the Securities Act), except pursuant to an exemption from the registration requirements of the Securities Act. Cautionary Note to U.S. Investors - The United States Securities and Exchange Commission permits oil and gas companies, in their filings with the SEC, to disclose only proved reserves that a company has demonstrated by actual production or conclusive formation tests to be economically and legally producible under existing economic and operating conditions. We use certain terms such as estimates of a mean of undiscovered natural gas and estimates of a mean of undiscovered oil that the SEC's guidelines strictly prohibit us from including in filings with the SEC. U.S. Investors are urged to consider closely the disclosure in our Form 10-K and other periodic reports filed by us from time to time with the SEC, available from us at www.sec.gov. You can also obtain this form from the SEC by calling 1-800-SEC-0330. Contacts: Investor Relations: Force Energy Corp. Rahim Rayani, President & CEO 1-866-953-FORC (3672) [email protected] www.forceenergycorp.com ------------------------------------------------------------------------------------------------------------------------------------------------------------ (NASDAQ: SNPS) Synopsys, Inc. Synopsys Introduces Synphony High Level Synthesis --Unique M-Language and Model-Based Solution Delivers Up to 10X Higher Productivity for Communications and Multimedia System Designers MOUNTAIN VIEW, Calif., Oct 12, 2009 -- Synopsys, Inc. (Nasdaq: SNPS), a world leader in software and IP for semiconductor design, verification and manufacturing, today introduced its Synphony HLS (High Level Synthesis) solution that integrates M-language and model-based synthesis to deliver up to 10X higher design and verification productivity than traditional RTL flows for communications and multimedia applications. Synphony HLS creates optimized RTL for ASIC and FPGA implementation, architecture exploration and rapid prototyping. In addition, Synphony HLS complements C/C++-based flows by generating C-models for system validation and early software development in virtual platforms. Synphony HLS integrates with Synopsys' Design Compiler(R), Synplify(R) Premier, Confirma(TM), VCS(R), System Studio and Innovator products to deliver the most comprehensive prototyping, implementation and verification flows from algorithm to silicon. The Synphony HLS solution delivers significantly higher productivity than traditional methods by providing benefits such as: -- An automated flow from M to optimized RTL -- Synthesis of optimized RTL architectures for ASIC and FPGA -- Rapid prototyping methodology for early algorithm validation -- C-model generation for early software development and fast system validation -- Unified verification across multiple flows including prototyping and ASIC implementation "The Synphony HLS solution will dramatically change how FPGAs and ASICs are used for system validation and embedded software development," said Richard Cagley, Ph.D., algorithm developer, Toyon Research Corporation. "Traditional HLS methodologies continue to incur significant hardware engineering resources to translate my algorithms to RTL for implementation into FPGA or ASIC silicon. Synphony HLS enables me to use MATLAB(R) for both high level simulation and production code, meaning that I can now go from simulation directly to hardware in a matter of hours or days instead of months or years. This has a vast impact on our productivity, schedules and quality of products based on our algorithms." Automated Flow from M-Language and High-level IP to Optimized RTL The Mathworks' MATLAB(R) environment has been broadly adopted for algorithm exploration and design because it allows concise expression of behavior at an extremely high level of abstraction. The M-language models developed in this environment are typically re-coded and re-verified at the RT Level (RTL) and in some cases in C/C++ for implementation and verification. Unlike inefficient and error-prone manual re-coding flows, Synphony HLS creates implementable RTL and C-models directly from high-level M-language code and the Synphony HLS-optimized IP model libraries. Using a unique constraint-driven fixed-point propagation feature, designers can quickly and intuitively derive fixed-point models from a synthesizable subset of high-level, floating-point M-code. The Synphony HLS engine will then synthesize architecturally optimized RTL to meet area, speed and power goals. Synphony HLS allows designers to stay in their preferred algorithm modeling language, eliminating the need to re-code and re-verify models and enabling early system-level validation and verification. High Level Synthesis from a Single Model The Synphony HLS engine can synthesize optimized architectures for ASIC, FPGA, rapid prototyping or virtual platforms while maintaining coherent verification through all levels of the implementation flow. Given the user-specified target and architectural constraints, the HLS engine automatically optimizes at multiple levels by applying pipelining, scheduling and binding optimizations across language and model boundaries, including M-language, IP blocks and throughout the design hierarchy. Synphony HLS for ASIC Design Synphony HLS includes a new advanced timing estimation capability that automatically utilizes Design Compiler for accurate information needed in automatic pipelining and rapid timing closure for a given ASIC technology. Synphony HLS for FPGA Design Synphony HLS includes advanced timing and device-specific optimizations for a broad range of FPGA families from Actel, Altera, Lattice and Xilinx. This includes optimized mapping to hardware multipliers, memories, shift registers and other advanced hardware resources in today's FPGA devices. Synphony HLS for Rapid Prototyping With Synphony HLS and Synopsys' technology-leading Confirma rapid prototyping solutions, design teams can quickly create a pre-silicon prototype of their design and start high- performance algorithm validation and software development much earlier in the design cycle. C-Output for Earlier Software Development and Faster System Validation Synphony HLS complements C/C++ implementation, verification and embedded software development flows by making C-model creation a natural byproduct of the development flow. Synphony HLS generates fixed-point ANSI-C models that can be used in a variety of system simulation environments and virtual platforms including Synopsys' Innovator, System Studio, VCS and SystemC flows. Thus Synphony HLS enables C-based verification and validation to start much earlier in the design cycle. "Until now, there has not been an automated way to derive a coherent verification flow across abstraction levels nor an implementation flow with optimized output from the very popular M language," said Gary Meyers, vice president and general manager of the Synplicity Business Group at Synopsys. "With Synphony HLS, we can provide a faster and more reliable path to system and software validation than competing solutions. Combined with Synopsys' technology-leading system prototyping and hardware-assisted verification solutions, design teams can more economically and more reliably design and verify their complex chips and software." Packaging and Availability Synphony HLS includes M-synthesis technology, C-model generation, the Synphony HLS high level IP model library and the Synphony HLS engine for ASIC and FPGA. Synphony HLS is now in limited customer availability with general availability by the end of calendar year 2009. For more information please visit www.synopsys.com/SynphonyHLS or contact your local Synopsys sales representative. About Synopsys Synopsys, Inc. (Nasdaq:SNPS) is a world leader in electronic design automation (EDA), supplying the global electronics market with the software, intellectual property (IP) and services used in semiconductor design, verification and manufacturing. Synopsys' comprehensive, integrated portfolio of implementation, verification, IP, manufacturing and field-programmable gate array (FPGA) solutions helps address the key challenges designers and manufacturers face today, such as power and yield management, software-to-silicon verification and time-to-results. These technology-leading solutions help give Synopsys customers a competitive edge in bringing the best products to market quickly while reducing costs and schedule risk. Synopsys is headquartered in Mountain View, California, and has more than 65 offices located throughout North America, Europe, Japan, Asia and India. Visit Synopsys online at http://www.synopsys.com/. This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including Synopsys' expectations of the benefits and availability of the Synphony HLS solution. These statements are based on current expectations and beliefs. Actual results could differ materially from these statements due to risks and uncertainties including, but not limited to, engineering difficulties, unforeseen difficulties in completing the commercial release of the solution and other risks as identified in the section of Synopsys' quarterly report on Form 10-Q for the fiscal quarter ended July 31, 2009, titled "Risk Factors." Statements included in this release are based upon information known to Synopsys as of the date of this release, and Synopsys assumes no obligation to publicly revise or update any forward-looking statement for any reason. Synopsys, Confirma, Design Compiler, Synplify and VCS are registered trademarks or trademarks of Synopsys, Inc. MATLAB and Simulink are registered trademarks of The MathWorks, Inc. Any other trademarks or registered trademarks mentioned in this release are the intellectual property of their respective owners. Editorial Contacts: Sheryl Gulizia Synopsys, Inc. 650-584-8635 [email protected] Stephen Brennan MCA 650-968-8900 x114 [email protected] ------------------------------------------------------------------------------------------------------------------------------------------------------------ (NASDAQ: SNTA) Synta Pharmaceuticals, Inc. BREAKING NEWS!! Synta Pharmaceuticals Announces Updated Elesclomol SYMMETRY(SM) Data Presented at Melanoma XIII LDH emerges as predictive factor for treatment with elesclomol in melanoma for both PFS and OS endpoints LEXINGTON, Mass., Oct 12, 2009 -- Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that additional results from its Phase 3 trial (SYMMETRY(SM)) of elesclomol in combination with paclitaxel in metastatic melanoma was presented at the Perspectives in Melanoma XIII Conference by Steven O'Day, M.D., principal investigator and Chief of Research and Director of the Melanoma Program at the Angeles Clinic in Santa Monica, California. "The data from the SYMMETRY trial presented at the Perspectives in Melanoma XIII Conference shows an important connection between patients' baseline level of LDH (lactate dehydrogenase), an established biomarker in melanoma, and treatment outcome with elesclomol," said Dr. O'Day. "Patients with low and normal baseline levels of LDH showed an improvement in progression free survival (PFS), the primary endpoint of the study. The OS (overall survival) data for these groups are still highly censored and evolving; no difference has been observed to date between the treatment and control arms. In contrast, patients with high baseline level of LDH showed no PFS benefit and a decreased survival time relative to the control arm. These results, along with the results of other recent randomized clinical trials, suggest that baseline LDH status may evolve from a prognostic factor for the disease to a potentially predictive factor for treatment. This could pave the way for a more personalized approach to treating this disease that considers markers such as LDH in determining an optimal approach to therapy." "We believe there are three emerging findings from the SYMMETRY trial that are important for the future of the elesclomol program," said Vojo Vukovic, M.D., Ph.D., Senior Vice President and Chief Medical Officer, Synta Pharmaceuticals. "First, there are clear signs of clinical benefit in the normal LDH population. In this patient group, which represents 68% of the trial population, the PFS endpoint was achieved. Second, any potential adverse effect on survival in favor of the control arm appears to be restricted to the high LDH patient population. Finally, and importantly in considering development of elesclomol beyond melanoma, there were no substantial differences in Grade 3 or 4 toxicities between the two arms of the trial, consistent with safety findings from prior trials, indicating that elesclomol was well tolerated." "Additional survival data, as well as a further understanding of the interaction between oxidative stress induction and LDH level, will be important for determining the future of the program," continued Dr. Vukovic. "Both the elesclomol oxidative stress mechanism and LDH relate to metabolic pathways. Together with our academic collaborators we are actively investigating the connection between the two, and expect to present initial results at scientific meetings later this year. We expect to present SYMMETRY survival data with 12 months minimum follow-up, and announce further decisions related to the future of the elesclomol program, in the first half of 2010." SYMMETRY Results Presented at Melanoma XIII Updated results for PFS, OS, response rate, and safety were presented, including prespecified exploratory analyses of the effects of baseline LDH levels on treatment outcomes. The complete presentation can be found at http://www.syntapharma.com/Documents/SYMMETRYPIM13.pdf. Progression Free Survival Updated progression free survival data showed no substantial changes from results presented May 30 this year at the American Society for Clinical Oncology meeting. Results for the overall Intent to Treat (ITT) population presented at the Melanoma XIII meeting showed a trend in favor of elesclomol in combination with paclitaxel as compared to paclitaxel alone (3.4 vs. 1.9 months, HR=0.88, p=0.188). The normal LDH population, 68% of patients, experienced a significant improvement in median PFS (3.6 vs. 2.1 months, HR=0.76, p=0.027). In contrast, the high LDH population, 32% of patients, showed no benefit (1.8 vs. 1.9 months, HR=1.10, p=0.549). Response Rate The Overall Response Rate (complete response plus partial response) was measured based on RECIST objective tumor response criteria for those patients with at least one follow-up assessment. Overall Response Rates for ELPAC vs. PAC were 7.4% vs. 4.4% for all randomized patients (N=595, p=0.121); 8.4% vs. 3.9% for the normal LDH population (N=407, p=0.065); and 5.3% vs. 5.4% for the high LDH population (N=188, p=1.00). Of the responders, two were complete responses, which occurred in the ELPAC arm in the normal LDH population; all other responses were partial responses. Overall Survival Survival results presented represent a minimum of six months follow-up since study termination on February 26, 2009. This data set shows a 55% censoring rate, indicating that results are not yet mature and may change. The hazard ratio in the full patient population (ITT analysis) is 1.17 (95% C.I. 0.93-1.48, p=0.173). The hazard ratio in the high LDH population (LDHgreater-than or equal to 1x ULN) is 1.49 (1.05-2.11); in the normal LDH population (LDH<1x ULN) is 0.99 (0.72-1.36); and in the low LDH population (LDHless-than or equal to 0.8x ULN) is 0.88 (0.58-1.34). At time of study termination in February 2009, 63% of randomized patients were off treatment. As a sensitivity analysis to explore the effect of study termination, the subgroup of patients enrolled before November 1, 2008 (N=422), which had the opportunity to receive a minimum of four cycles of treatment, was examined. 83% of this population was off treatment at the time of study termination. Results from this analysis were presented at the meeting and showed that differential impact of baseline LDH levels on overall survival outcomes persisted, with high LDH patients performing most poorly and low LDH patients performing most favorably. Safety Elesclomol was well-tolerated in the SYMMETRY trial and most observed adverse events were NCI CTC (National Cancer Institute Common Toxicity Criteria) Grade 1 or 2. The most common Grade 3 or higher adverse events in the treatment arm (elesclomol plus paclitaxel) compared to the control arm (paclitaxel alone) were neutropenia (6.8% vs. 2.5%), fatigue (4% vs. 1.2%), anemia (2.2% vs. 1.8%), dyspnea (2.2% vs. 1.8%), alopecia (1.9% vs. 2.8%), peripheral neuropathy (1.9% vs. 1.2%), vomiting (1.9% vs. 1.5%), and infusion related reaction (1.9% vs. 2.2%). SYMMETRY Trial Design The SYMMETRY trial enrolled patients with stage IV metastatic melanoma who had not received prior chemotherapy but who may have already been treated with non-chemotherapeutic agents such as biologics. The blinded, randomized, controlled study, was conducted at approximately 160 centers in 15 countries. Patients were randomized (1:1) to elesclomol (213 mg/m(2)) plus paclitaxel (80 mg/m(2)) or paclitaxel alone (80 mg/m(2)) and received three weekly treatments and one week without treatment per each four week cycle. If tolerated, treatment continued until disease progression. Patients were stratified according to LDH levels, M-grade status and prior treatment history. Responses were assessed using standard RECIST criteria at baseline and at a minimum every eight weeks, with radiology scans being assessed by independent, blinded, reviewers at a central site. The primary endpoint of the study was progression-free survival; overall survival and tumor response rate were secondary endpoints. The SYMMETRY trial and other trials for elesclomol were suspended in February 2009 following a meeting of an independent Data Monitoring Committee for the SYMMETRY trial in which an imbalance in deaths in favor of the control (paclitaxel alone) arm was observed. About Elesclomol Elesclomol is a first in class oxidative stress inducer that triggers apoptosis (programmed cell death) in cancer cells. Cancer cells operate at high levels of reactive oxygen species, or oxidative stress. Elesclomol is believed to act by increasing the level of oxidative stress in cancer cells even further, beyond sustainable levels, inducing apoptosis. This mechanism of action, called oxidative stress induction, represents a novel way of selectively targeting and killing cancer cells. In a double-blind, randomized, controlled Phase 2b clinical trial in 81 patients with stage IV metastatic melanoma, elesclomol in combination with paclitaxel met the primary endpoint, doubling the median time patients survived without their disease progressing, compared to paclitaxel alone (p = 0.035). The most common adverse events in the elesclomol plus paclitaxel group included fatigue, alopecia, constipation, nausea, hypoaesthesia, arthralgia, insomnia, diarrhea, and anemia. About Oxidative Stress Elesclomol increases the generation of reactive oxygen species (ROS) such as oxygen radicals in cells. These ROS cause signaling leading to an increase in pro-apoptotic factors, a decrease in anti-apoptotic factors, and ultimately to the initiation of programmed cell death via the mitochondrial apoptosis pathway. By elevating ROS and altering the balance of apoptotic signaling factors, elesclomol can both trigger apoptosis and enhance the sensitivity of cancer cells to certain conventional anti-cancer agents. Normal, non-cancer cells typically have very low levels of ROS and have a high antioxidant capacity. In contrast, cancer cells generally have much higher levels of ROS and exist in a state of oxidative stress, leaving them vulnerable to any further increases in ROS. About Metastatic Melanoma Melanoma, the most deadly form of skin cancer, arises from melanocytes, the pigment-producing cells of the skin. According to the American Cancer Society, melanoma accounts for approximately five percent of all skin cancers but causes about 75% of all skin cancer-related deaths. An estimated 60,000 people will be diagnosed and nearly 8,200 people will die from melanoma this year in the U.S. alone. If diagnosed and surgically removed while localized in the outermost skin layer, melanoma is potentially curable; however, for patients with metastatic disease the prognosis is poor, with limited available treatments and an expected survival of only six to nine months. The incidence of melanoma has increased more rapidly than any other cancer during the past ten years. About Synta Pharmaceuticals Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. Synta has a unique chemical compound library, an integrated discovery engine, and a diverse pipeline of clinical- and preclinical-stage drug candidates with distinct mechanisms of action and novel chemical structures. All Synta drug candidates were invented by Synta scientists using our compound library and discovery capabilities. For more information, please visit www.syntapharma.com. Safe Harbor Statement This media release may contain forward-looking statements about Synta Pharmaceuticals Corp. Such forward-looking statements can be identified by the use of forward-looking terminology such as "will", "would", "should", "expects", "anticipates", "intends", "plans", "believes", "may", "estimates", "predicts", "projects", or similar expressions intended to identify forward-looking statements. Such statements, including statements relating to the timing, developments and progress of our clinical and preclinical programs, reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such forward-looking statements, including those described in "Risk Factors" of our Form 10-K for the year ended December 31, 2008 as filed with the Securities and Exchange Commission. Synta undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise, except as required by law. SOURCE: Synta Pharmaceuticals Corp. CONTACT: Synta Pharmaceuticals Corp. Rob Kloppenburg, 781-541-7125 ------------------------------------------------------------------------------------------------------------------------------------------------------------ (NASDAQ: SNTS) Santarus, Inc. BREAKING NEWS!! Santarus Inc executes licence agreement for ZEGERID products in Europe Oct 12, 2009 -- US biopharmaceutical company Santarus Inc (NASDAQ:SNTS) said on Monday that it has entered into a licensing agreement with Norgine B.V., a European pharmaceutical company, for ZEGERID immediate-release omeprazole products in Europe. The company has granted Norgine the exclusive rights to develop, manufacture and commercialise prescription immediate-release ZEGERID products incorporating the proton pump inhibitor omeprazole in combination with one or more buffering agents in specified markets in Western, Central and Eastern Europe. A Norgine will pay Santarus an upfront fee of USD2.5m. In addition Santarus will be entitled to receive up to USD10m in milestone payments upon the achievement of certain regulatory events, subject to reductions based on Norgine's actual costs directly related to its clinical, regulatory and reimbursement efforts for a "major" country as defined under the agreement. A Santarus will also receive tiered royalties ranging from the mid- to high-teens, subject to reduction in certain limited circumstances, on net sales of any products sold under the licence agreement. ------------------------------------------------------------------------------------------------------------------------------------------------------------ (NASDAQ: SNWL) SonicWALL, Inc. BREAKING NEWS!! SonicWALL Solutions Now Rated 'Avaya Compliant' --SonicWALL UTM and VPN Solutions are Now Compatible with Multiple key Avaya IP Telephony Solutions SAN JOSE, Calif., Oct 12, 2009 -- SonicWALL, Inc. (Nasdaq: SNWL), a leading secure network infrastructure company, today announced that its Unified Threat Management (UTM) and IPSec VPN solutions are compliant with key Internet protocol (IP) telephony solutions from Avaya, a leading global provider of business communications applications, systems and services. SonicWALL's TZ, Network Security Appliance (NSA) and E-Class NSA series product lines combine firewall, UTM, wireless and VPN technology to deliver comprehensive protection and maximum performance to customer networks. These product lines are now compliance-tested by Avaya for compatibility with: -- Avaya Aura(TM) Communication Manager Branch 2.0 -- Avaya Aura(TM) Communication Manager 5.2 with Avaya Aura(TM) SIP Enablement Services 5.2 (SES) -- Avaya IP Telephony Infrastructure using Avaya IP Office 4.2 in a Converged VoIP and Data Network "These certifications with Avaya broaden the scope of SonicWALL's participation in the VoIP market space and validates our UTM solutions in securing networks supporting voice, video and data," said Patrick Sweeney, vice president of product management with SonicWALL. "With SonicWALL's UTM solutions, our customers have the security, control and access necessary for managing today's converged networks." One of the companies benefiting from the interoperability of SonicWALL and Avaya solutions is Office Solutions, Inc., a business that specializes in designing and implementing converged voice and data solutions. "Using the SonicWALL product for our interoffice connectivity and our Avaya PBX made our installation less time consuming and seamless," said Ron Mazzaccaro, vice president for Office Solutions. "It made it easy to turn up our five locations with the SonicWALL NSA product line. Everything works perfectly." SonicWALL is a member of the Avaya DevConnect program--an initiative to develop, market and sell innovative third-party products that interoperate with Avaya technology and extend the value of a company's investment in its network. As a Gold member of the program, SonicWALL is eligible to submit products for compatibility testing by the Avaya Solution Interoperability and Test Lab in Lincroft, N.J. There a team of Avaya engineers develops a comprehensive test plan for each application to verify whether it is compliant with Avaya established standards. This compatibility testing process allows users to confidently add best-in-class capabilities to their network without having to replace their existing infrastructure--speeding deployment of new applications and reducing both network complexity and implementation costs. "By offering compliance testing to the many innovative companies like SonicWALL who are members of our DevConnect program, Avaya promotes fully interoperable solutions that help businesses unleash powerful new possibilities," said Eric Rossman, vice president, developer relations and technical alliances, Avaya. "They are able to use Unified Communications to connect employees and customers to information from wherever they are, over whatever device they have available - getting more out of their multivendor network and delivering new value to their bottom line." About Avaya Avaya is a global leader in enterprise communications systems. The company provides unified communications, contact centers, and related services directly and through its channel partners to leading businesses and organizations around the world. Enterprises of all sizes depend on Avaya for state-of-the-art communications that improve efficiency, collaboration, customer service and competitiveness. For more information please visit www.avaya.com. For more information on the Avaya DevConnect program, visit www.avaya.com/devconnect. About SonicWALL, Inc. SonicWALL, Inc. the leader in network security, focuses on developing solutions that remove the cost and complexity out of managing a secure network environment. With over one million award-winning appliances shipped through its global network of ten thousand channel partners, SonicWALL provides end-to-end solutions including Firewalls, SSL VPN's, Email Security and Continuous Data Protection that collectively ensure robust, secure network protection. For more information, visit the company web site at http://www.sonicwall.com/. Safe Harbor Regarding Forward-Looking Statements Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements include but are not limited to statements regarding the impact of Avaya certification on the benefits of SonicWALL solutions in the VoIP market; the ability to streamline interoffice productivity; the benefits associated with SonicWALL participation in the Avaya DevConnect program; and the benefits associated with the Avaya compatibility testing process. These forward-looking statements are based on the opinions and estimates of management at the time the statements are made and are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. In addition, please see the "Risk Factors" described in our Securities and Exchange Commission filings, including our Annual Report on Form 10-K for the year ended December 31, 2008, for a more detailed description of the risks facing our business. All forward-looking statements included in this release are based upon information available to SonicWALL as of the date of the release, and we assume no obligation to update any such forward-looking statement. NOTE: SonicWALL is a registered trademark of SonicWALL, Inc. Other product and company names mentioned herein may be trademarks and/or registered trademarks of their respective companies. SOURCE SonicWALL, Inc. ------------------------------------------------------------------------------------------------------------------------------------------------------------ (NASDAQ: SRCL) Stericycle, Inc. BREAKING NEWS!! Stericycle Launches Carbon Footprint Estimator for U.S. Hospitals to Assess Environmental Impact --Tool is available to any U.S. acute-care hospital wanting to build or improve green programs LAKE FOREST, Ill., Oct 12, 2009 -- Stericycle, Inc. (Nasdaq: SRCL) launched its Carbon Footprint Estimator, designed to encourage hospitals to assess their current carbon impact and to determine ways to lessen their CO2 footprint. As hospitals explore environmental practices, "green teams" are seeking ways to improve facility practices and policies. Yet few tools exist that specifically help determine a hospital's environmental impact. Global awareness of the negative effects of CO2 and other greenhouse gas emissions is still evolving. Many different industry calculators analyze the benefits of total greenhouse gas emissions, yet despite the presence of over 5,000 hospital and healthcare facilities in the U.S., few tools are available to specifically help hospitals account for their environmental impact. Stericycle's Carbon Footprint Estimator (http://www.stericycle.com/carbon-footprint-estimator.html) is designed to help any U.S. hospital determine the amount of plastic, associated cardboard containers, and CO2 emissions they would keep out of the environment. The healthcare facility can accomplish this by modifying the facility's utilization of sharps containers by switching to Stericycle reusable containers versus disposable containers. No password is required for a hospital to use the tool. The tool's website had more than 600 unique visitors since it launched in June. The Estimator was highlighted at the American Healthcare Resources and Materials Management, American Society for Healthcare Environmental Services and the Association for Professionals in Infection Control and Epidemiology conferences this year. By providing a minimal amount of public information, a Stericycle customer measures its diminished environmental impact based on actual container utilization. A non-customer would obtain an estimate of its potential diminished footprint. An average 200-bed acute care hospital will divert more than 13,000 pounds of CO2 or the equivalent to the emission from 679 gallons of gasoline. Hospitals with green initiatives are seeking to make a difference to staff, patients and the community as well as physicians who admit patients to various hospitals and appreciate green practices. In a recent independent survey sponsored by Stericycle, 100% of hospital respondents with the Stericycle Sharps Management Service using Bio Systems reusable containers said the number of needle sticks occurring during sharps disposal decreased significantly. Seventy-seven percent said they experienced between 0-1 needle sticks on an annual basis. Additionally, 91% of infection control and environmental services respondents indicated that this service is a clinical best practice. According to Brenda Helms, infection control coordinator for employees at The Heart Hospital of Baylor in Plano, Texas, "We chose Stericycle's Sharps Management System using Bio Systems reusable containers to decrease the amount of bio-hazardous waste and the risk of overfilled containers to our staff. We also believe in being green," she concludes. Another U.S. hospital commented on the use of Bio Systems reusable containers, "Our hospital's clean and green campaign has decreased the carbon footprint for our community by 41,000 pounds of plastic that did not go into the landfill last year," says Alyssa Pickles, director of infection control at Tallahassee Memorial Healthcare. Landfill waste is a major concern; with landfills accounting for 23% of methane gas emissions in 2007. To date, Stericycle's reusable sharps program has kept more than 72 million disposable containers out of landfills, while preventing 123 million pounds of carbon from being expelled into the atmosphere and 6.3 million gallons of gas from being burned; the equivalent of a 25-mpg car driving around the Earth ten times. These numbers climb every day. Another equally important green issue for hospitals assessing their environmental impact is pharmaceutical waste. With state laws being passed, hospitals are beginning to implement programs like the Stericycle Pharmaceutical Waste Compliance Service that enable the facility to appropriately dispose of unused or expired medications that are identified as waste so as not to get into the public waste water system. About Stericycle Lake Forest, IL-based Stericycle (NASDAQ: SRCL) is a leader in healthcare-related services that protect people and reduce risk. With more than 430,000 customers worldwide, Stericycle has operations in North America, Europe, and Latin America. Visit www.stericycle.com. Safe Harbor Statement: Statements in this press release may contain forward-looking statements that involve risks and uncertainties, some of which are beyond our control (for example, general economic conditions). Our actual results could differ significantly from the results described in the forward-looking statements. Factors that could cause such differences include changes in governmental regulation of medical waste collection and treatment and increases in transportation and other operating costs, as well as the other factors described in our filings with the U.S. Securities and Exchange Commission. As a result, past financial performance should not be considered a reliable indicator of future performance, and investors should not use historical trends to anticipate future results or trends. We make no commitment to disclose any subsequent revisions to forward-looking statements. Contact: Kellee Johnson, The Ballast Group, 312-751-3959 or [email protected]. SOURCE Stericycle, Inc. ------------------------------------------------------------------------------------------------------------------------------------------------------------ About StockMarketingInc.com StockMarketingInc.com is a website that profiles stocks of interest. We are not licensed brokers or financial consultants. The information here is believed to be reliable, but not guaranteed to be accurate by tockMarketingInc.com. Please be advised that the information contained may or may not be complete and is solely for informational purposes only. This is not to be construed as an offer to sell, hold or the solicitation of an offer to buy. Investors are encouraged to seek opinions by their registered brokers or financial advisors after extensive due diligence is performed. ((Comments on this story may be sent to [email protected])) (c) 2009 M2 COMMUNICATIONS |